Targeting CXCR4 with [ 68 Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?

C-X-C motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer. This study investigated the feasibility of CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) using [ ⁶⁸ Ga]Pentixafor in malignant pleural mesothelioma. Six patients with pleural mesothelioma underwent [ ⁶⁸ Ga]Pentixafor-PET/CT. 2'-[ ¹⁸ F]fluoro-2'-deoxy-D-glucose ([ ¹⁸ F]FDG)-PET/CT (4/6 patients) and immunohistochemistry obtained from biopsy or surgery (all) served as standards of reference. Additionally, 9 surgical mesothelioma samples were available for histological work-up. Whereas [ ¹⁸ F]FDG-PET depicted active lesions in all patients, [ ⁶⁸ Ga]Pentixafor-PET/CT recorded physiologic tracer distribution and none of the 6 patients presented [ ⁶⁸ Ga]Pentixafor-positive lesions. This finding paralleled results of immunohistochemistry which also could not identify relevant CXCR4 surface expression in the samples analyzed. In contrast to past reports, our data suggest widely absence of CXCR4 expression in pleural mesothelioma. Hence, robust cell surface expression should be confirmed prior to targeting this chemokine receptor for diagnosis and/or therapy.
Competing Interests: CONFLICTS OF INTEREST HJW is founder and shareholder of Scintomics. SKr is CEO of Scintomics. All other authors declare no conflict of interest.